|
|
|
DRNA - Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. (DRNA) is a biopharmaceutical company that specializes in the development of RNA interference (RNAi) therapies. The company is based in Lexington, Massachusetts, and its stock is traded on the NASDAQ stock exchange.
Dicerna Pharmaceuticals is focused on developing treatments for rare, inherited diseases that are caused by genetic mutations. The company's proprietary GalXC RNAi platform is designed to target and silence disease-causing genes in a highly specific manner. Dicerna Pharmaceuticals has a pipeline of drug candidates that are currently in clinical trials for a range of rare diseases, including alpha-1 antitrypsin deficiency and primary hyperoxaluria type 1.
As of February 25, 2023, Dicerna Pharmaceuticals has a market capitalization of approximately $1.8 billion. The company's stock price has been volatile in recent years, reflecting the risk associated with investing in clinical-stage biopharmaceutical companies.
Dicerna Pharmaceuticals has a highly experienced management team and a strong scientific and clinical development program. The company has also forged several strategic partnerships with major pharmaceutical companies, including Roche and Novo Nordisk, to help fund and advance its research and development efforts.
As with any investment in a biopharmaceutical company, there are some risks associated with investing in Dicerna Pharmaceuticals, including the possibility that the company's drug candidates may not be successful in clinical trials or may not be approved by regulatory agencies. However, Dicerna Pharmaceuticals' innovative RNAi platform and pipeline of drug candidates make it an attractive investment opportunity for investors seeking exposure to the biopharmaceutical industry.
|
|
|
|
|
